Clinical Observation of Whole Brain Radiotherapy Concomitant with Targeted Therapy for Brain Metastasis in Non-small Cell Lung Cancer Patients with Chemotherapy Failure

Abstract

Objective: To investigate the clinical effects of whole brain radiotherapy concomitant with targeted therapy for brain metastasis in non-small cell lung cancer (NSCLC) patients with chemotherapy failure. Materials and Methods: Of the 157 NSCLC patients with chemotherapy failure followed by brain metastasis admitted in our hospital from January 2009 to August 2012, the combination group (65 cases) were treated with EGFR-TKI combined with whole brain radiotherapy while the radiotherapy group (92 cases) were given whole brain radiotherapy only. Short-term effects were evaluated based on the increased MRI in brain 1 month after whole brain radiotherapy. Intracranial hypertension responses, hematological toxicity reactions and clinical effects of both groups were observed. Results: There were more adverse reactions in the combination group than in radiotherapy group, but no significant differences were observed between the two groups in response rate (RR) and disease control rate (DCR) (P>0.05). Medium progression free survival (PFS), medium overall survival (OS) and 1-year survival rate in combination group were 6.0 months, 10.6 months and 42.3%, while in the radiotherapy group they were 3.4 months, 7.7 months and 28.0%, respectively, which indicated that there were significant differences in PFS and OS between the two groups (P<0.05). Additionally, RPA grading of each factor in the combination group was a risk factor closely related with survival, with medium PFS in EGFR and KRAS mutation patients being 8.2 months and 11.2 months, and OS being 3.6 months and 6.3 months, respectively. Conclusions: Whole brain radiotherapy concomitant with target therapy is favorable for adverse reaction tolerance and clinical effects, being superior in treating brain metastasis in NSCLC patients with chemotherapy failure and thus deserves to be widely applied in the clinic.Keywords: Non-small cell lung cancer -brain metastasis -whole brain radiotherapy -targeted therapy -clinical effect

Expression of ERCC1, RRM1 and LRP in Non-small Cell Lung Cancers and their Influence on Chemotherapeutic Efficacy of Gemcitabine Concomitant with Nedaplatin

“…Lung cancers rank the top of cancer-related death with increasing morbidity around the world (Aydiner et al, 2013;Cai et al, 2013;Kaya et al, 2013;Mutlu et al, 2013;Natukula et al, 2013;Oven et al, 2013;Unal et al, 2013;Wang et al, 2013). At present, the chemotherapeutic protocols for NSCLC mainly apply platinums as basic drugs combining with the third generation chemotherapeutic drugs such as paclitaxel, gemcitabine and vinorelbine, etc..…”

Meta-analysis of Six Randomized Control Trials of Chemotherapy Plus Anti-HER Monoclonal Antibody for Advanced Gastric and Gastroesophageal Cancer

“…To improve the positive impact on the overall tolerability of therapy and potentially survival, targeted therapies represent its special advantage as a promising method. Whole brain radiotherapy concomitant with targeted therapy improved PFS and OS compared with radiotherapy group in brain metastasis patients (Cai et al, 2013). Over the past decade, the EGFR has been primary focus for biologically targeted therapies, with the most active treatments being monoclonal antibodies.…”

Radiosensitization Effect of Overexpression of Adenovirus-mediated SIRT6 on A549 Non-small Cell Lung Cancer Cells

“…NSCLC patients take up 80%~85% of total cases in lung cancer (Mutlu et al, 2013;Oven et al, 2013;Aydiner et al, 2013;Cai et al, 2013;Kaya et al, 2013;Natukula et al, 2013;Unal et al, 2013;Wang et al, 2013) and patients with locally advanced NSCLC who can't receive surgery were mainly treated with radiotherapy, the effect of which was mainly marked with dose-dependence. Although highdose radiotherapy can improve the remission rate and local control rate, at the same time, it can bring about severe side effects, such as severe radiation esophagitis and radiation pneumonitis (Feng et al, 2011).…”